Clinical Outcomes of Small Cell Carcinoma of the Genitourinary Tract and the Prognostic Significance of the Tumor Immune Microenvironment
Cancer Research and Treatment · 2024
DOI: 10.4143/crt.2023.1076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, 2024. Verfasst von Jaewon Hyung und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Carcinoma, Small Cell, Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
Small cell carcinoma of the genitourinary tract (GU SCC) is a rare disease with a poor prognosis. There are only limited treatment options due to insufficient understanding of the disease. In this study, we analyzed the clinical outcomes of patients with GU SCC and their association with the tumor immune phenotype.Materials and Methods Patients diagnosed with GU SCC were included. Survival outcomes according to the primary location (prostate and non-prostate) and stages (limited disease [LD] and extensive disease [ED]) were analyzed. We performed multiplex immunohistochemistry (IHC) in non-prostate SCC patients and analyzed the immune cell population.
Results
A total of 77 patients were included in this study. Their median age was 71 years, 67 patients (87.0%) were male, and 48 patients (62.3%) had non-prostate SCC. All patients with ED (n=31, 40.3%) received etoposide plus platinum (EP) as initial treatment and median overall survival (OS) was 9.7 months (95% confidence interval [CI], 7.1 to 18.6). Patients with LD (n=46, 59.7%) received EP followed by radiotherapy or surgery, and 24-months OS rate was 63.6% (95% CI, 49.9 to 81.0). The multiplex IHC analysis of 21 patients with non-prostate SCC showed that patients with a higher density of programmed death-ligand 1–expressing CD68+CD206+ M2-like macrophages had significantly worse OS outcomes with an adjusted hazards ratio of 4.17 (95% CI, 1.25 to 14.29; adjusted p=0.02).
Conclusion
Patients with GU SCC had a poor prognosis, even those with localized disease. The tumor immune phenotypes were significantly associated with survival. This finding provides new insights for treating GU SCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Asan Institute of Life Sciences, Asan Medical Center, Seoul, Korea.
Zitieren
APA
Hyung, J., Kim, H. D., Kim, G. H., Cho, Y. M., Ryu, Y. M., Kim, S. Y., Park, I., Yoon, S., & Lee, J. L. (2024). Clinical Outcomes of Small Cell Carcinoma of the Genitourinary Tract and the Prognostic Significance of the Tumor Immune Microenvironment. Cancer Research and Treatment. https://doi.org/10.4143/crt.2023.1076
Vancouver
Hyung J, Kim HD, Kim GH, Cho YM, Ryu YM, Kim SY, et al. Clinical Outcomes of Small Cell Carcinoma of the Genitourinary Tract and the Prognostic Significance of the Tumor Immune Microenvironment. Cancer Research and Treatment. 2024. doi:10.4143/crt.2023.1076
BibTeX
@article{Hyung2024,
author = {Hyung, Jaewon and Kim, Hyung-Don and Kim, Gi Hwan and Cho, Yong Mee and Ryu, Yeon-Mi and Kim, Sang-Yeob and Park, Inkeun and Yoon, Shinkyo and Lee, Jae Lyun},
title = {Clinical Outcomes of Small Cell Carcinoma of the Genitourinary Tract and the Prognostic Significance of the Tumor Immune Microenvironment},
journal = {Cancer Research and Treatment},
year = {2024},
doi = {10.4143/crt.2023.1076}
}
EUVIMED